SVRA•benzinga•
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?
Summary
Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 27, 2025 by benzinga